Adaptive Biotechnologies Corp

ADPT.US
Healthcare · Diagnostics & Research
22.52
-0.02 (-0.09%)
USD · NASDAQ

Company Information

Company Name
Adaptive Biotechnologies Corp
Sector
Healthcare
Industry
Diagnostics & Research
Exchange
NASDAQ
ISIN: US00650F1093
CIK: 0001478320
CUSIP: 00650F109
Currency: USD
Full Time Employees: 624
Phone: 206 659 0067
Fiscal Year End: December
IPO Date: Jun 27, 2019
Description:

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Address:

1165 Eastlake Avenue East, Seattle, WA, United States, 98109

People

Directors & Officers

Name Title Year Born
Mr. Chad M. Robins M.B.A. Co-Founder, CEO & Chairman 1975
Ms. Julie Rubinstein President & COO 1972
Dr. Harlan S. Robins Ph.D. Co-Founder & Chief Scientific Officer 1973
Mr. Kyle Piskel VP, CFO & Principal Accounting Officer 1984
Ms. Susan Bobulsky Chief Commercial Officer of MRD 1981
Mr. Christopher Carlson Ph.D. Founder NA
Ms. Karina Calzadilla Vice President of Investor Relations NA
Ms. Clarice McCauley Head of Legal, Corporate Secretary, VP & Chief Compliance Officer NA
Mr. Francis T. Lo Chief People Officer 1981
Dr. Sharon Benzeno Ph.D. Chief Commercial Officer of Immune Medicine 1974

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 24, 2026 Julie Rubinstein N/A Sale 19.06K $14.02 $267.22K
Apr 22, 2026 Julie Rubinstein N/A Sale 19.06K $14.13 $269.32K
Apr 21, 2026 Julie Rubinstein N/A Sale 30.94K $14.66 $453.60K
Apr 20, 2026 Julie Rubinstein N/A Sale 19.06K $14.55 $277.32K
Apr 16, 2026 Julie Rubinstein N/A Sale 19.06K $14.18 $270.27K
Apr 13, 2026 Julie Rubinstein N/A Sale 19.06K $13.15 $250.64K
Apr 10, 2026 Julie Rubinstein N/A Sale 19.06K $12.77 $243.40K
Apr 08, 2026 Julie Rubinstein N/A Sale 30.94K $14.83 $458.86K
Apr 08, 2026 Harlan S Robins N/A Sale 10.00K $14.85 $148.50K
Apr 08, 2026 Francis Lo N/A Sale 22.56K $15.07 $340.04K
Apr 08, 2026 Chad M Robins N/A Sale 37.26K $15.19 $566.02K
Apr 07, 2026 Julie Rubinstein N/A Sale 19.06K $13.56 $258.45K
Apr 06, 2026 Chad M Robins N/A Sale 83.33K $14.41 $1.20M
Apr 01, 2026 Julie Rubinstein N/A Sale 19.06K $14.45 $275.42K
Mar 23, 2026 Julie Rubinstein N/A Sale 19.06K $13.83 $263.60K
Mar 20, 2026 Julie Rubinstein N/A Sale 19.06K $13.37 $254.83K
Mar 18, 2026 Julie Rubinstein N/A Sale 19.06K $13.18 $251.21K
Mar 16, 2026 Julie Rubinstein N/A Sale 19.06K $13.41 $255.59K
Mar 13, 2026 Julie Rubinstein N/A Sale 19.06K $12.96 $247.02K
Mar 11, 2026 Chad M Robins N/A Sale 470.17K $13.17 $6.19M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Viking Global Investors LP 29.99M Mar 31, 2026 4.69% $1.16 0.00%
BlackRock Inc 13.30M Mar 31, 2026 2.08% $0.00 -0.23%
Vanguard Group Inc 11.28M Dec 31, 2025 1.76% $0.00 0.06%
Vanguard Capital Management, LLC 6.09M Mar 31, 2026 0.95% $0.00 0.00%
Westfield Capital Management Company, L.P. 5.44M Mar 31, 2026 0.85% $0.32 33.89%
Vanguard Portfolio Management, LLC 4.49M Mar 31, 2026 0.70% $0.00 0.00%
Amvescap Plc. 4.45M Mar 31, 2026 0.70% $0.01 43.20%
Wellington Management Company LLP 3.86M Mar 31, 2026 0.60% $0.01 78.15%
Geode Capital Management, LLC 3.64M Mar 31, 2026 0.57% $0.00 3.54%
Lord, Abbett & Co LLC 3.54M Mar 31, 2026 0.55% $0.16 14.78%
The Goldman Sachs Group Inc 3.24M Mar 31, 2026 0.51% $0.01 11.71%
State Street Corp 3.23M Mar 31, 2026 0.50% $0.00 1.43%
Ameriprise Financial Inc 3.02M Mar 31, 2026 0.47% $0.01 16.46%
BNP Paribas Investment Partners SA 2.69M Mar 31, 2026 0.42% $0.04 0.00%
ARK Investment Management LLC 2.09M Mar 31, 2026 0.33% $0.23 -2.15%
Fred Alger Management, LLC 2.06M Mar 31, 2026 0.32% $0.13 -8.12%
Arrowstreet Capital Limited Partnership 2.00M Mar 31, 2026 0.31% $0.02 -17.62%
D. E. Shaw & Co LP 1.97M Mar 31, 2026 0.31% $0.02 3.31%
Delaware Management Holdings Inc 1.88M Mar 31, 2026 0.29% $0.04 -3.05%
Driehaus Capital Management LLC 1.75M Mar 31, 2026 0.27% $0.18 -36.58%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Total Stock Mkt Idx Inv 4.84M 0.76% ▲ 4.24% Jun 30, 2026
2 iShares Russell 2000 ETF 3.98M 0.62% ▲ 0.60% Jun 30, 2026
3 ARK Genomic Revolution ETF 2.03M 0.32% ▲ 3.01% Jun 30, 2026
4 ARK Genomic Revolution 2.00M 0.31% ▼ 0.24% Jun 30, 2026
5 Vanguard Small Cap Index 1.75M 0.27% ▲ 3.79% Jun 30, 2026
6 Xtrackers MSCI World Swap ETF 1C 1.59M 0.25% ▼ 0.63% Dec 31, 2025
7 Alger Small Cap Focus I 1.49M 0.23% ▲ 0.00% Apr 30, 2026
8 Alger Small Cap Focus Composite 1.49M 0.23% ▲ 0.00% Apr 30, 2026
9 Fidelity Small Cap Index 1.48M 0.23% ▲ 0.88% Apr 30, 2026
10 iShares Russell 2000 Growth ETF 1.42M 0.22% ▼ 0.38% Jun 30, 2026

Financial Highlights

Market Cap: $3.61B
EBITDA: $-29.79M
PEG Ratio: $0.00
Book Value: $1.36
Earnings/Share: $-0.32
Profit Margin: -16.82%
Operating Margin: -27.10%
ROA (TTM): -5.74%
ROE (TTM): -23.96%
Revenue (TTM): $295.41M
Revenue/Share (TTM): $1.93
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 35.10%

Valuation Metrics

Enterprise Value: $3.42B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 160.04M
Shares Float: 125.80M
% Insiders: 138.40%
% Institutions: 9,551.20%
Short % Float: 8.99%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$276.98M
Cost of Goods Sold
adjust
$-71.36M
Gross Profit
subtotal
$205.62M
SG&A
adjust
$-72.70M
R&D
adjust
$-93.77M
Other Operating Expense
adjust
$-96.27M
Operating Income
subtotal
$-57.12M
Other / Non-Operating Items
adjust
$-2.38M
Net Income
subtotal
$-59.50M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about ADPT.US!